Sino Biopharm's drug gains breakthrough designation in China

Sino Biopharmaceutical's Rovadicitinib has received breakthrough therapeutic designation from China's drug regulator for chronic graft-versus-host disease.

Phase III trials for the condition are ongoing in China, with Phase II trials approved in the US. Clinical data shows 86.4% overall response and 85.2% 12-month failure-free survival rates.